Resverlogix value decimated by RVX-208 failure
This article was originally published in Scrip
Executive Summary
Resverlogix lost nearly all of its value on 27 June when its stock sank 92.6% from $2.99 to $0.22 per share – dropping its market cap from $221.9 million to $16.4 million in one and a half hours of trading – after the Canadian company disclosed the failure of its lead cardiovascular drug candidate and only clinical asset RVX-208 in the Phase IIb ASSURE study.
You may also be interested in...
Finance Watch: Tetraphase Reorganization Follows Troubled Antibiotic Commercialization Path
Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for its second life science fund, Provention calls off post-ADA offering and Oncologie raises $80m series B.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.